Fundraising Fox
🦊/People
Sign in

Alexandra (Sandra) Glucksmann

Investor

Advisory Partner at Adjuvant Capital · Board director at Sensorium Therapeutics · Executive at Editas Medicine

Boston

Find your path to Alexandra

401 people in our graph share verified history with Alexandra — schools, employers, funds. One of them is your warm intro.

Hemant TanejaunlockedAlexandra: together at Massachusetts Institute of Technology (1993)
×4Alexandra: together at Massachusetts Institute of Technology
Alexandra: together at University of Chicago
Alexandra: together at Tufts University School of Medicine

About

Sandra Glucksmann joined Adjuvant Capital as an Advisory Partner and Investment Committee member in 2023, and is CEO of Sensorium Therapeutics. She has over 30 years in biotech, serving as founding CEO and President of Cedilla Therapeutics and founding COO of Editas Medicine. She holds a Ph.D. in molecular genetics and cell biology from the University of Chicago.

Invests in

Biotech

Board director at Sensorium Therapeutics

Intro paths

→

In turn, Alexandra can intro founders to Sensorium Therapeutics's investors below.

Sensorium Therapeutics's investors · 8

Bonaventure Equity, LLCRaleigh · since 2021Hatteras Venture PartnersResearch Triangle · $500K – $4M checks · since 2021Iter InvestmentsSouth Florida · since 2021Mission BiocapitalSan Francisco · $500K checks · since 2021Route 66 VenturesAlexandria · $500K – $4M checks · since 2021Sante Health VenturesAustin · since 2025Sante VenturesAustin · $2M – $6M checks · since 2022Service Provider CapitalVail · since 2021

Co-founders at Sensorium Therapeutics

JRJerrold Rosenbaum
Jerrold RosenbaumDirector
JHJacob Hooker
Jacob HookerExecutive Officer, Director

Executive at Editas Medicine

Intro paths

→

In turn, Alexandra can intro founders to Editas Medicine's investors below.

Editas Medicine's investors · 6

Deerfield Management CompanyNew York · since 2015EcoR1 CapitalSan Francisco · since 2015Flagship VenturesCambridge · since 2015National Institutes of Health (NIH)since 2015Polaris PartnersBoston · $500K – $5M checks · since 2013Sofinnova VenturesMenlo Park · $100K – $15M checks · since 2015

Co-founders at Editas Medicine

FZFeng Zhang
Feng ZhangScientific Founder, Core Member, Broad Institute of MIT and Harvard
GCGeorge Church
George ChurchScientific Founder, Professor of Genetics, Harvard University and MIT
KJ
Keith JoungScientific Founder, Professor of Pathology, Harvard Medical School
DLDavid Liu
David LiuScientific Founder, Professor of Chemistry and Chemical Biology, Harvard University

Experience

  1. Rouge TherapeuticsBoard Executive Chaircurrent2025 — presentNetherlands
  2. Tufts University School of MedicineTUSM Board of Advisorscurrent2024 — presentBoston, Massachusetts, United States
  3. REGENXBIO Inc.Independent Board Membercurrent2018 — presentRockville, MD
  4. Adjuvant CapitalAdvisory Partnercurrent2023 — presentUnited States
  5. Edity TherapeuticsBoard Membercurrent2022 — presentRehovot, Israel
  6. Scenic BiotechSenior Advisorcurrent2024 — presentAmsterdam, North Holland, Netherlands
  7. Scenic BiotechIndependent Board Member2017 — 2024The Randstad, Netherlands
  8. Sensorium TherapeuticsBoard Member and Senior Advisor2025
  9. Sensorium TherapeuticsPresident & CEO2023 — 2025Boston, Massachusetts, United States
  10. Cedilla TherapeuticsPresident and CEO2018 — 2022Cambrdige, MA
  11. WEST - Women in the Enterprise of Science and TechnologyMember Board of Directors2017 — 2020Cambridge, MA
  12. WEST - Women in the Enterprise of Science and TechnologyChair Board of Directors2006 — 2017Cambridge, MA
  13. Third Rock VenturesEntrepreneur In Residence2017 — 2018
  14. Editas MedicineChief Operating Officer2013 — 2017
  15. TaconicIndependent Board Member2006 — 2015
  16. Cerulean PharmaSenior VP Research and Development2006 — 2013Cambridge, MA
  17. Cerulean PharmaSenior VP Research & Business Operations2006 — 2011
  18. Millennium PharmaceuticalsFrom Scientist to VP1993 — 2006

Skills & more

Research1Biotechnology32Lifesciences8Commercialization5Technology Transfer5Medical Devices3Molecular Biology7Biochemistry5Start-ups5Cross-functional Team Leadership4Oncology7Biopharmaceuticals16
+3 moreDrug DiscoveryProduct DevelopmentPharmaceutical Industry

Languages Spanish

From Alexandra's professional profile.

Investments

Board seats

REGENXBIOScenic Biotech

Per the firm's website.

Colleagues at Adjuvant Capital

Abrar Haque
Associate at Adjuvant Capital
Christian Mandl
Senior Advisor at Adjuvant Capital
Curt LaBelle
Venture Partner at Adjuvant Capital
Evelyn Yanatos
Director of Finance and Compliance at Adjuvant Capital
Gerard Cunningham
Operating Partner at Adjuvant Capital
Giulia Balconi
Associate at Adjuvant Capital
Glenn Rockman
Co-Founder and Partner at Adjuvant Capital
Jim Robinson
Senior Advisor at Adjuvant Capital

Frequently asked questions

Who is Alexandra (Sandra) Glucksmann?
Sandra Glucksmann joined Adjuvant Capital as an Advisory Partner and Investment Committee member in 2023, and is CEO of Sensorium Therapeutics. She has over 30 years in biotech, serving as founding CEO and President of Cedilla Therapeutics and founding COO of Editas Medicine. She holds a Ph.D. in molecular genetics and cell biology from the University of Chicago.
Where does Alexandra (Sandra) Glucksmann work?
Alexandra (Sandra) Glucksmann is Advisory Partner at Adjuvant Capital and Board director at Sensorium Therapeutics and Executive at Editas Medicine.
What does Alexandra (Sandra) Glucksmann invest in?
Alexandra (Sandra) Glucksmann invests in Biotech.
What boards does Alexandra (Sandra) Glucksmann sit on?
Alexandra (Sandra) Glucksmann holds tracked board seats at REGENXBIO, Scenic Biotech.
Where did Alexandra (Sandra) Glucksmann go to school?
Alexandra (Sandra) Glucksmann studied at Massachusetts Institute of Technology (Post-doctoral fellow, Molecular Biology); University of Chicago (PhD Molecular Genetics and Cell Biology); University of Wisconsin-Madison (Bachelor of Science - BS).

Founder mafias

Same school

Shared employers